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Abstract
Pluripotent stem cells (PSCs) hold significant promise in regenerative medicine due to their unlimited capacity for self-
renewal and potential to differentiate into every cell type in the body. One major barrier to the use of PSCs is their potential
risk for tumor initiation following differentiation and transplantation in vivo. In the current study we sought to evaluate the
role of the tumor suppressor Pten in murine PSC neoplastic progression. Using eight functional assays that have previously
been used to indicate PSC adaptation or transformation, Pten null embryonic stem cells (ESCs) failed to rate as significant in
five of them. Instead, our data demonstrate that the loss of Pten causes the emergence of a small number of aggressive,
teratoma-initiating embryonic carcinoma cells (ECCs) during differentiation in vitro, while the remaining 90–95% of
differentiated cells are non-tumorigenic. Furthermore, our data show that the mechanism by which Pten null ECCs emerge
in vitro and cause tumors in vivo is through increased survival and self-renewal, due to failed repression of the transcription
factor Nanog.
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Introduction
Risk of tumor formation constitutes one of the major barriers to
the use of pluripotent stem cell (PSC) lines in regenerative
medicine. To date, only a small number of groups have focused on
developing tools, or identifying molecular pathways that cause
mouse or human PSC lines to undergo cultural adaptation and
neoplastic progression [1,2,3,4,5,6,7,8,9]. One of the major
measures of PSC neoplastic progression is the acquisition of
aneuploidy identified through routine karyotyping, or by subkar-
yotypic changes identified by techniques such as comparative
genomic hybridization [1,4,10]. Accompanying these molecular
diagnostic tools are emerging functional in vitro assays for
distinguishing aneuploid or adapted PSC lines from euploid
parental lines. These include efficiency of re-plating from single
cells, growth rate, dependence on exogenous growth factors,
reduced levels of spontaneous differentiation, colony appearance,
apoptosis and in some cases CD30 surface marker expression
[1,4,5,6,8,9,10,11]. More recently, in vivo assays that monitor
teratoma size and numbers of failed-to-differentiate cells called
embryonic carcinoma cells (ECCs) within PSC-derived teratomas
have been successfully used to confirm the identity of adapted PSC
lines [4,7,8].
Neoplastic progression of differentiated somatic cells used for
cell based therapy is a critical problem [4]. However, failure to
execute differentiation in a small fraction of cells that could
contaminate the donor cells used for transplantation is also critical
to PSC tumorigenicity, as the most common tumor type
documented after transplantation of differentiated donor cells
derived from PSCs are teratomas [3,12,13,14,15,16]. In one study
using murine induced pluripotent stem (iPS) cells, it was shown
that the number of Nanog-positive ECCs that persisted during
neurosphere differentiation in vitro correlated with teratoma
formation of the transplanted neurospheres in vivo [3]. However,
the mechanism by which persistent ECCs survive during
differentiation is not known. In recent work, we determined that
the emergence of ECCs in vivo from PSC-induced teratomas is
associated with reduced expression of the tumor suppressor
phosphatase and tensin homologue (Pten) [17]. Therefore, in the current
study, our goal was to determine the consequence of Pten null
mutations in tumorigenicity of differentiated murine embryonic
stem cells (ESCs).
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Materials and Methods
Cells
Pten+/+ and 2/2 ESC were previously published [18]. Pten
short hair-pin (shp) knockdown cells were generated by transfect-
ing Pten+/+ cells with a lentivirus containing a Pten specific shp
construct. ESCs were maintained on mitomycin C treated
fibroblast feeders in Knockout DMEM (Invitrogen) containing
15% Defined lot tested FBS (Hyclone Lot # ATJ 33070), 1 X non
essential amino acids (Invitrogen), 1X Pen/Strep (Invitrogen), 1 X
L-Glutamine (Invitrogen), 55 mM beta-mercaptoethanol (Invitro-
gen), and 1000 units/ml LIF (Chemicon). Differentiation involved
plating cells in ESC media minus LIF, plus 10 mM retinoic acid
(Sigma) for four days without changing the media.
Karyotype
G-banded karyotyping was performed by Cell Line Genetics
(http://www.clgenetics.com) (Madison, WI). Cells were submitted
for karyotype by first culturing off feeders for one passage in T-25
flasks. Cells were shipped overnight in ESC media as live cells, and
Cell Line Genetics subsequently performed metaphase spreads
and Gimsea staining before counting 20 metaphases for each cell
line to determine karyotype.
Generation of teratomas
Ethics Statement: Surgery was performed following Institutional
Approval for Appropriate Care and use of Laboratory animals by
the UCLA Institutional Animal Care and Use Committee
(Chancellor’s Animal Research Committee (ARC)), Animal
Welfare assurance number A3196-01. Briefly, for testicular
tumors, a single incision was made in the peritoneal cavity and
the testis was pulled through the incision site. Using a 27-gauge
needle, 56105 ESCs, or fewer, in a volume of 50 ml 0.5X Matrigel
(BD) were transplanted into the testis of adult SCID mice. Four to
six weeks after surgery, mice were euthanized and the tumors
removed for histology, flow cytometry and immunohistochemistry.
Flow cytometry and cell sorting
A single cell suspension of the cell lines was generated by
digestion for 5 minutes at 37uC in 5% CO2 in 0.25% Trypsin
EDTA (Invitrogen). Single cell suspensions of tumors were
generated by dissection of the tumor into 1 mm2 pieces followed
by incubation in 1 mg/ml collagenase in high glucose DMEM for
2 hours at 37uC in 5% CO2. Cells were centrifuged for 5 min at
1000 rpm and resuspended in PBS with 1% BSA. For extracel-
lular staining, SSEA1 (1:100 DSHB) and c-kit (1:200 BD-
Pharmagen) antibodies were used for 1–2 million cells per ml of
PBS/BSA. Cells were incubated with antibody for 20 minutes at
4uC, washed, incubated for 5 minutes at 4uC in PBS/BSA and
washed again. Cy5 conjugated goat anti mouse IgG and IgM
(1:500) and PE conjugated goat anti rat IgG (1:1000) (both Jackson
ImmunoResearch) were used. Internal staining for Oct4 was
performed using the Cytoperm/Cytofix Kit (BD). Primary Oct4
(N-19) antibody (Santa Cruz) was used at 1:100 and FITC
conjugated donkey anti goat secondary antibody (Jackson
ImmunoResearch) was used at 1:200. Cells were incubated with
secondary antibody for 20 minutes, washed and resuspended in
PBS/BSA for analysis on a BD Biosciences LSR II. Annexin V
staining (BD Annexin V kit) was performed according to
manufacturers instructions. Cells were prepared for FACS as for
flow cytometry with the following exceptions. 7AAD was added to
samples to exclude dead cells from sorts. For some samples MACS
bead conjugated to SSEA1 antibody (Miltenyi Biotech) was added
to the cells at a ratio of 20 ml antibody to 80 ml staining buffer per
16107 cells and incubated at 4uC for 20 minutes. Fluorescent
secondary antibody was then added and incubated for 20 minutes
at 4uC. Cells were then washed and resuspended in staining buffer.
MACS separation was performed on MS columns in a
MiniMACS separation unit (Miltenyi Biotech) following the
manufacturer’s instructions. Samples enriched for SSEA1 were
then sorted on a Becton Dickenson FACS-ARIA.
Histology and Immunofluorescence
Tumors were fixed in 4% paraformaldehyde for at least
24 hours at room temperature. Tissue was embedded in paraffin
and 5 mm sections were cut for analysis. Sections were stained with
hematoxylin and eosin for histology. For immunofluorescence,
sections were deparafinized and re-hydrated followed by antigen
retrieval in 10 mM Tris Base, 1 mM EDTA, 0.05% Tween 20 at
95uC for 40 minutes. Sections were washed in 20 mM Tris-HCl
pH 7.4, 0.15 mM NaCl and 0.05% Tween 20, permeablized in
0.1% Triton X-100 in PBS and blocked in 5% normal donkey
serum, 0.05% Tween in PBS. Primary antibodies against SSEA1
(1:100 – DSHB) and Oct3/4 (1:100 – Santa Cruz Biotech) were
incubated on the sections for 16 hours at 4uC. Sections were
incubated in species specific FITC or TRITC conjugated
secondary antibodies (Jackson ImmunoResearch) at 1:200 for
1 hour at room temperature. Sections were mounted in Prolong
Gold Anti-fade Reagent with DAPI (Invitrogen) and photo-
graphed on an LSM 510 confocal microscope.
Generation of secondary testicular tumors by serial
transplantation
SSEA1 positive cells from primary tumors were isolated by
Magnetic Activated Cell Sorting (MACS) following labeling with
primary antibody against SSEA1. SSEA1+ cells were then labeled
with a magnetic bead conjugated rat anti-mouse IgM secondary
antibody (Miltenyi Biotech). 2.56105 SSEA1 positive cells were re-
transplanted in 50 ml of 0.5X Matrigel. All experiments were
completed at 6–8 weeks following transplantation.
RT- and Semi-Quantitative Real Time PCR
RNA was extracted using the RNeasy Mini Kit (Qiagen) and
reverse-transcribed with Superscript II Reverse Transcriptase
(Invitrogen). For RT PCR, following reverse transcription, PCR
was performed on the samples using the primers Oct4 (F59
AGTCTGGAGACCATGTTTCTGAAGT R59 TACTCTTCT-
CGTTGGGAATACTCAATA), Nanog (F59CAGAAAAACCAG-
TGGTTGAAGACTAG R59 GCAATGGATGCTGGGATAC-
TC), Sox2 (F59CACAACTCGGAGATCAGCAA R59CTCCGG-
GAAGCGTGTACTTA) and Gapdh (F59ACCACAGTCCAT-
GCCATCAC R59TCCACCACCCTGTTGCTGTA). For semi-
quantitative Real Time PCR, PCR was performed on the cDNA
according to the manufacturer’s protocol using a BioRad iQ
iCycler with Taqman probes for Gapdh, Grb10, Asb4, Slc16a12 and
Tspan8 (ABI) or SYBR Green (Roche Applied Science) and Gapdh,
Oct4, Sox2 and Nanog primers.
Western blot
Protein was extracted using M-PER cell lysis reagent (Thermo
Scientific, Rockford, IL). Protein concentration was measured
using the Pierce BCA Protein assay (Thermo Scientific, Rockford,
IL) and 25 mg of total protein was subjected to electrophoresis on
12% NuPAGE Novex Bis-Tris gels (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions. Protein was transferred
to Hybond ECL nitrocellulose (Amersham, Buckinghamshire,
UK) at 4uC using NuPAGE transfer buffer according to
Pten and Tumor Initiation after Differentiation
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16478
manufacturer’s instructions (Invitrogen). For immunoblotting,
membranes were blocked in Tris buffered saline (TBS) pH 7.4
containing 0.1% Tween 20 (Sigma) (TBST) containing 5%
Carnation Milk Powder and 10% Fetal bovine serum. Primary
antibodies: Pten, phospho Pten, pan Akt, phospho Akt S308,
phospho Akt T473, phospho Pdk1, phospho p53 S15, phospho
Gsk3b S9 (all Cell Signaling), Nanog and b-actin (both Abcam)
and Oct4 (Santa Cruz), were incubated with the membranes in
5% BSA or milk buffer at 4uC overnight. Membranes were
washed 3x in TBST before adding secondary antibodies
conjugated to peroxidase for 1 hour in milk buffer. Membranes
were then washed three times in TBST before incubation in ECL
Western blotting Analysis Reagent (Amersham, Buckinghamshire,
UK) according to manufacturer’s instructions. Membranes were
placed next to Hyperfilm (Amersham, Buckinghamshire, UK) for
at least 5 minutes prior to developing.
Intracellular Lactate Assay
Cells were grown in mESC media or in differentiation media on
gelatin for 4 days. 200,000 cells were analyzed for each condition
in triplicate. Intracellular lactate was assayed using the BioVision
Lactate Assay Kit according to manufacturers instructions. OD
570 was analyzed using a Molecular Devices SpectraMAX Plus
plate reader.
Microarray
All Microarray data is MIAME compliant and the raw data is
deposited at GEO (GSE25465). Microarray targets were prepared
using Nu-GEN WT-OvationH FFPE RNA Amplification System
and FL-OvationH cDNA Biotin Module V2, and then hybridized
to the Affymetrix Mouse Genome 430 2.0 Array. Data analyses
were performed using PartekH Genomics Suite Version 6.4. Three
biological replicates were analyzed for each cell types. Differen-
tially expressed genes between RA treated SSEA1/c-kit positive
Pten+/+ and 2/2 ESCs were selected at $1.5 fold and p,0.05.
Bio-functional analysis was performed using Ingenuity pathways
Analysis 7.6.
siRNA knockdown
Cells were plated at 50,000 cells/well of a 6 well plate in
differentiation media containing 10 mMRA. One day later, 5 ml of
10 mM ON-TARGETplus Non-targeting Pool and Nanog ON-
TARGETplus SMARTpool (Thermo Scientific) siRNAs were
added using 3 ml of Dharmafect 1 (Thermo Scientific) per well
according to manufacturer’s instructions. Cells were harvested on
day 4 and analyzed as in previous experiments.
Results
Pten2/2mESC proliferate faster than wild type PSCs and
generate larger teratomas
One of the most robust measures of neoplastic progression of
PSCs under self-renewing conditions is faster growth rate and to
some extent protection from apoptosis. Therefore, in the first set of
experiments, karyotypically normal wild type and Pten2/2 ESCs
(Fig. 1A) were subjected to proliferation and apoptosis assays. We
confirmed previous results [18], that Pten2/2 and Pten shRNA
knockdown ESCs have a faster growth rate under self-renewing
conditions compared to wild type (Fig. 1B). However, this was not
accompanied by decreased apoptosis using Annexin V staining
(Fig. 1C). Next, we addressed whether Pten2/2 ESCs exhibit
reduced spontaneous differentiation under self-renewing condi-
tions by evaluating SSEA1 and Oct4 expression in individual cells
by flow cytometry (Fig. 1D). Our results show that Pten2/2 ESCs
are equivalent to wild type, and loss of Pten does not promote
resistance to spontaneous differentiation in the presence of LIF. To
address re-plating efficiencies, we sorted single SSEA1 positive
ESCs into 96 well plates at 10 cells per well using FACS, and
counted colony forming potential of the re-plated ESCs following
alkaline phosphatase staining (Fig. 1E). These results show that re-
plating efficiency of undifferentiated ESCs is equivalent between
wild type and Pten2/2 cells under self-renewing conditions.
In order to test teratoma initiating potential, we transplanted
56105 wild type or Pten2/2 ESCs into testes of SCID mice
(Fig. 1F–G). Quantification of total tumor burden revealed that
Pten2/2 ESC teratomas were approximately 3 fold larger than
wild type at 6 weeks (Fig. 1F) (n = 6). Analysis of the tumors by
histology revealed robust differentiation into all three germ layers,
indicating that Pten2/2 ESCs are capable of lineage differenti-
ation as teratomas in vivo (Fig. 1G). ECC emergence in teratomas
in vivo following transplantation of human PSCs is a hallmark of
neoplastic progression [4,7]. In contrast to human PSCs,
transplantation of murine ESCs or murine egg cylinders results
in teratomas that contain obvious clusters of failed-to-differentiate
ECCs that can be serially transplanted [8,17,19]. The differences
between mouse and human ESCs in this assay is not clear and may
be due to host compatibility or an inherent difference between
species. Therefore, given that diploid mouse ESC derived-
teratomas contain ECCs, we next explored whether generation
of teratomas from undifferentiated Pten2/2 ESCs results in an
increase in the percentage of ECCs in teratomas relative to wild
type. Immunofluorescence of teratoma sections revealed that both
wild type and Pten2/2 tumors contained clusters of ECCs that co-
stain for SSEA1 and Oct4 (Fig. 1G). Flow cytometry for SSEA1 in
tumors derived from mutant and wild type ESCs revealed that the
percentage of SSEA1 positive cells was not significantly different
between mutant (5.6863.0) and wild type (4.4562.2) tumors
(n = 5) (Fig. 1G). In order to evaluate teratoma-initiating potential
of the ECCs derived from the primary teratomas, we sorted freshly
dissected tumors and re-transplanted the SSEA1 positive cells into
host SCID mice without intervening culture. Our data demon-
strate that the ECCs from both genotypes are tumorigenic and can
reconstitute immature teratomas that are indistinguishable from
the primary tumors and from each other (Fig. S1). Taken together,
using six previously reported functional assays for neoplastic
progression of PSCs (proliferation rate, protection from apoptosis,
protection from spontaneous differentiation, increased colony
forming potential, increased teratoma size and increased propor-
tion of ECCs in teratomas), only proliferation rate and increased
teratoma size were found to associate with ESCs containing a null
mutation in Pten.
Pten2/2 cells are capable of generating teratomas post-
differentiation
Given that differentiation is the first step in using PSCs for
regenerative medicine, we assayed teratoma-initiating potential of
wild type and Pten2/2 ESCs following differentiation in vitro.
Differentiation was conducted for four days in the presence of
10 mM retinoic acid (RA) without LIF. No difference was seen in
the morphology of differentiating Pten wt and2/2 ESCs (Fig. S2).
To determine if there was a difference in teratoma formation
ability of wild type and Pten2/2 differentiated cells, 56105
differentiated cells were transplanted into SCID mice. Visual
inspection and quantification of testicles transplanted with
differentiated cells indicated that tumors only developed in
testicles transplanted with differentiated Pten2/2 ESCs and not
wild type ESCs. Testicles transplanted with Pten2/2 differenti-
ated cells were five times larger than unmanipulated testicles or
Pten and Tumor Initiation after Differentiation
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Figure 1. Pten null mutant ESCs generate larger tumors than wild type with a similar rate of in vivo ECC generation. (A) Karyotype of
wild type and Pten2/2 ESCs (B) Proliferation of Pten+/+, 2/2 and shp knockdown murine ESCs under self renewing conditions. (C) Annexin V
staining by flow cytometry on day 4 in self-renewing culture. (D) SSEA1 and Oct4 staining by flow cytometry on day 4 of self-renewing culture. (E) Re-
plating assay showing numbers of wells with alkaline phosphatase (AP) positive colonies 6 days after sorting 10 cells/well into a 96 well plates. (F)
Total tumor weight after 6 weeks. Pten2/2 tumors were significantly larger by non-parametric analysis. (G) Testicular tumor derived from wild type
or Pten2/2 ESCs (Scale bar = 0.5 cm). Histology of tumors showing derivatives of ectoderm (ecto), mesoderm (meso) and endoderm (endo)
(Magnification 2006). Immunofluorescence for SSEA1 and Oct4 in tumor sections and percentage SSEA1+ by flow cytometry (mean 6 SD)
(Magnification 4006). ** = p,0.005, N/S = not significant.
doi:10.1371/journal.pone.0016478.g001
Pten and Tumor Initiation after Differentiation
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testicles transplanted with differentiated wild-type cells of equal
cell number (Fig. 2A). By histology we show that testicles
transplanted with differentiated wild type cells contained no
evidence of tumor formation, however in 1/4 samples (shown), we
identified a plug of fibroblast-like cells that were non-invasive and
did not stain for pluripotency markers (Fig. 2B). In contrast,
transplantation of differentiated Pten2/2 cells resulted in invasive
immature teratomas that destroyed most of the testicular tissue.
These teratomas contained a small SSEA1+/Oct4+ ECC
component that was serially transplantable in 9/9 transplants
(Fig. 2C).
In order to determine whether the teratoma-initiating potential
in the differentiated population was due to an increased number of
failed to differentiate cells in vitro as shown for transformed iPS cells
[3], we performed flow cytometry for Oct4 and SSEA1 on day 4 of
differentiation, and found no statistically significant difference in
the percentage of SSEA1 positive cells or SSEA1/Oct4 double
positive cells compared to wild type (Fig. 3A). Furthermore, RT-
PCR at days 2 and 4 of differentiation in wild type and Pten2/2
cells suggested that repression of pluripotent transcription factor
Oct4, Nanog and Sox2 RNA at day 4 of differentiation was similar
between the two genotypes indicating that the Pten2/2 cells do
not have an intrinsic defect in the ability to repress pluripotent
transcription factor RNA levels in the majority of differentiating
cells (Fig. 3B). Next we examined protein levels and phosphory-
lation status of members of the PI3k/Akt pathway as well as Oct4
and Nanog during in vitro differentiation. The activating post-
translational phosphorylation of Serine 308 and Threonine 473 on
Akt were increased in Pten2/2 differentiated cells at days 2, 3 and
4 of differentiation relative to wild type (Fig. 3C). However,
repression of Nanog and Oct4 protein in the general population
during differentiation was not overtly affected by loss of Pten
(Figure 3C), in agreement with the RT-PCR data (Figure 3B).
It has been proposed that the high glycolytic activity in cancer
cells is due to increased activity of Akt [20] and it has been shown
that embryonic stem cells have high glycolytic activity in the
undifferentiated (tumorigenic) state and lower glycolytic activity in
the differentiated (non-tumorigenic) state [21,22]. To examine if
metabolism is affected in the absence of Pten, we performed an
intracellular lactate assay and found that Pten2/2 differentiated
cells have significantly higher levels of lactate relative to wild type
(Figure 3D).
The tumorigenic differentiated Pten2/2 cells are
confined to a small population
To determine if tumorigenicity can be assigned to a subpop-
ulation of differentiated cells, we transplanted the SSEA1 positive
and negative fractions separately into SCID mice (Figure 3E).
Initially we compared sorted SSEA1 positive cells from wild type
and Pten2/2 differentiated cultures at 500,000 cells per
transplant, and determined that teratoma inducing ability was
exclusively found in differentiated SSEA1 positive cells that lacked
Pten and not wild type. Next we compared tumor-initiating
potential between SSEA1 positive and negative cells following
differentiation of Pten2/2 ESCs for four days in RA. Our results
show teratoma-initiating ECC potential is not equal between the
sorted populations, and instead ECCs are found exclusively in the
SSEA1 positive fraction of Pten2/2 differentiated cells with
SSEA1 negative cell fractions not forming tumors at all (Fig. 3E).
While the teratoma-initiating potential was confined to the
SSEA1 positive fraction, teratoma-initiating ability was attenuated
when using 100,000 cells (Fig. 3E). This suggests that not every
SSEA1 positive cell is tumorigenic. Therefore, in order to more
specifically define the ECC population within the SSEA1 fraction,
we examined expression of the surface marker c-kit, as this
receptor is also expressed on carcinoma in situ, the precursors of
testicular germ cell tumors called teratocarcinomas, the malignant
counterpart of teratomas [23]. Using flow cytometry we identified
three times as many SSEA1/c-kit double positive cells in the wild
type samples relative to Pten2/2 at day 4 of differentiation
(Fig. 4A). Paradoxically, this is opposite to what would have been
predicted for a cell population that functionally has increased
capacity for inducing teratomas [3]. This effect was specific to
differentiated cells as no difference was observed in the percentage
Figure 2. Differentiation of Pten null mutant ESCs does not abolish tumor formation. (A) Tumor burden of differentiated wild type and
Pten2/2 ESCs. Pten2/2 tumors were significantly larger by non-parametric analysis. (B) Non-invasive plug of cells identified after transplanting
differentiated wild type cells (Magnification 2006). Immunofluorescence of plug showing no residual undifferentiated cells (Magnification 4006). (C)
Histology of teratocarcinomas generated after transplanting differentiated Pten2/2 ESCs (Magnification 2006). Immunofluorescence showing
clusters of failed to differentiate SSEA1/Oct4 positive cells in tumors (Magnification 4006).
doi:10.1371/journal.pone.0016478.g002
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of SSEA1/c-kit double positive cells when cultured in the self-
renewing undifferentiated state (Day 0) (Fig. 4A). To examine the
tumorigenic potential of the SSEA1/c-kit double positive cells, we
sorted and transplanted 10,000 SSEA1/c-kit double positive
(sample 1 and 3), or SSEA1 positive c-kit negative cells (samples
2 and 4). Teratoma-initiating potential was enriched in the
SSEA1/c-kit double positive population and never observed in
SSEA1+ cells negative for c-kit (Fig. 4B). Furthermore, teratomas
derived from Pten 2/2 SSEA1/c-kit double positive cells were
larger than wild type, and were metastatic indicating that despite
the lower numbers of SSEA1/c-kit double positive cells that
emerged following in vitro differentiation of Pten2/2 cells, the
tumorigenic potential of this double positive population is
significantly greater than wild type. In order to generate a rapid
in vitro assay for recapitulating the increased teratoma-inducing
potential of SSEA1/c-kit Pten2/2 differentiated cells, we designed
a re-plating assay in which ESCs were differentiated in the
presence of RA for four days and 100 SSEA1/c-kit double positive
cells/well were plated as single cells into 96 well plates. Colony
forming ability was assessed 6 days after re-plating by alkaline
phosphatase staining (Fig. 4B). Using this second assay, we clearly
show that Pten2/2 differentiated teratoma-initiating ECCs have 5
times greater colony forming potential than wild type cells,
suggesting increased capacity for ECC survival and self renewal
over wild type (Fig. 4B).
In order to determine whether pluripotent gene expression was
altered in the SSEA1/c-kit double positive Pten2/2 differentiated
cells relative to wild type, we examined the expression of Oct4,
Nanog and Sox2 by semi-quantitative real time PCR (Fig. 4C and
data not shown). Our results indicate that unlike the majority of
Figure 3. Pten2/2 cells are able to down-regulate pluripotency genes normally upon differentiation and the tumorigenic
population of differentiated cells is confined to the SSEA1 positive cells. (A) Flow cytometry to evaluate percentage of SSEA1 and Oct4/
SSEA1 double positive cells in the differentiated population on day 4 of differentiation. (B) RT-PCR on days 0, 2 and 4 of differentiation for Oct4,
Nanog, Sox2 and Gapdh. (C) Western blot comparing wild type and Pten2/2 cells at days 0, 2, 3 and 4 days of differentiation in the presence of
retinoic acid (RA). (D) Intracellular lactate in undifferentiated and RA differentiated wild type and Pten2/2 ESCs normalized to intracellular lactate on
day 0 in wild type. (E) Diagram of procedure used and table of tumor formation from SSEA1+ or – cells from Pten+/+ and2/2 differentiated cultures.
N/S = not significant.
doi:10.1371/journal.pone.0016478.g003
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differentiated cells, which repress these transcription factors
(Fig. 3B), Nanog and Oct4 mRNA exhibited a modest yet
statistically significant increase in differentiated Pten2/2
SSEA1/c-kit double positive cells (sample 3) relative to differen-
tiated SSEA1/c-kit wild type sorted cells (sample 1) (Fig. 4C). Sox2
showed no statistically significant change relative to wild type (data
not shown). Interestingly, we found that expression of Nanog was
significantly higher in the tumorigenic SSEA1/c-kit double
Figure 4. The SSEA1/c-kit double positive subpopulation of Pten2/2 differentiated cells is responsible for tumorigenicity. (A) Flow
plots showing SSEA1 and c-kit expression of wild type and Pten2/2 cells on day 4 of differentiation in 10 mM RA. Percentage of SSEA1/c-kit double
positive cells on day 4 of differentiation and undifferentiated (Day 0) cultures. (B) Tumor weight of 10,000 transplanted cells and graph indicating
number of wells containing alkaline phosphatase positive colonies 6 days after sorting 100 cells into each well of a 96 well plate. 4 fractionated
populations (1–4) used as indicated in flow plots in A. (C) Semi-quantitative real time PCR for Nanog and Oct4 in the fractionated populations as
indicated in panel A. (D) Semi-quantitative real time PCR for Nanog in Pten2/2 cells on day 4 of differentiation following addition of a control or
Nanog specific siRNA pool. (E) Re-plating assay showing number of AP positive colonies using 5000 SSEA1/ckit positive cells/well of a 6 well plate
from day 4 differentiated Pten2/2 cells with control or Nanog specific siRNAs. (F) Tumor weight and images of testes transplanted with 500,000
differentiated Pten2/2 cells with control or Nanog specific siRNAs. Arrowhead indicates tumor generated from Nanog siRNA treated cells. (G) PCA
map of microarray on SSEA1+/c-kit+ wild type and Pten2/2 differentiated cells. * = p,0.05 ** = p,0.005, N/S = not significant.
doi:10.1371/journal.pone.0016478.g004
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positive cells (sample 3) compared to the non-tumorigenic SSEA1
positive c-kit depleted cells (sample 4), suggesting that expression of
Nanog specifically associates with tumorigenicity in this model. To
test the role of Nanog in the tumorigenicity of the Pten2/2 ECCs,
we knocked down Nanog during differentiation of Pten2/2 cells in
the presence of RA and evaluated colony forming potential of the
emerging ECCs. Using Nanog specific siRNAs we were able to
knockdown Nanog RNA by 93% relative to scrambled siRNA
controls on day 4 of differentiation (Fig. 4D). To test whether
Nanog repression by siRNAs attenuated ECC emergence during
differentiation, we re-plated 5000 SSEA1/c-kit double positive
Pten2/2 differentiated cells in 6-well plates, and identified a
significant 10-fold reduction in the numbers of alkaline phospha-
tase positive colonies derived from the Pten2/2 Nanog siRNA
treated differentiated cultures verses the control Pten2/2
differentiated cultures (Fig. 4E). To determine if the knockdown
of Nanog during differentiation would reduce the tumorigenic
potential of the Pten2/2cells in vivo, we transplanted 500,000
Pten2/2 cells differentiated for 4 days with either control or Nanog
siRNAs. Teratomas formed in 10 of 10 transplants with the
control siRNAs (as expected from Fig. 2A and C). In contrast, only
1 of 10 transplants resulted in a tumor following treatment with
Nanog specific siRNAs (Fig. 4F). Thus we were able to significantly
reduce the tumorigenicity of Pten2/2 cells by differentiating in
the presence of siRNAs against Nanog.
Finally, in order to identify additional downstream effectors in
the Pten2/2 ECCs that emerge with differentiation, we
performed microarray analysis comparing wild type and mutant
SSEA1/c-kit double positive sorted cells after 4 days of
differentiation in RA (Fig. 4G). Using principle component
analysis (PCA) of the replicate samples of each genotype we found
that the wild type and mutant samples clustered separately, with
85 unique genes distinguishing wild type and mutant SSEA1/c-kit
sorted cells on day 4 of differentiation (Tables S1 and S2). The
microarray was confirmed by semi-quantitative real-time PCR
(Figure S3). Gene ontology analysis of these 85 genes identified
functional groups again associated with cholesterol metabolism,
response to nutrient levels and endogenous stimuli, regulation of
cell growth, pyruvate metabolic processes and stem cell mainte-
nance and development.
Discussion
In the current study we evaluated ESCs with a null mutation in
Pten in eight functional assays that have previously been used to
distinguish culture adapted or transformed human and mouse
PSCs from wild type (Table S3). The majority of these assays are
conducted under self-renewing (undifferentiated) conditions, with
only three assays evaluating tumorigenicity of differentiated cells.
Our data demonstrate that Pten2/2 ESCs exhibit hallmarks of
neoplastic progression in just 3/8 assays when compared to wild
type diploid ESCs. Furthermore, using differentiation and
evaluation of failed-to-differentiate cells, the Pten2/2 differenti-
ated ESC samples paradoxically contain fewer tumor-initiating
SSEA1/c-kit double positive ECCs relative to wild type cells in
vitro. Transcriptionally, we show that the Pten2/2 ECCs have
modest yet significantly higher expression levels of Nanog and Oct4
mRNA, and functionally show that Pten2/2 ECCs have greater
capacity for survival and self renewal in tumor and colony forming
replating assays. Critically, we find that the emergence of ECCs in
the Pten2/2 cells during differentiation in vitro can be significantly
attenuated by differenting in the presence of Nanog siRNAs.
Together, our data demonstrate that it is not necessarily the
number of failed-to-differentiate cells that contribute to increased
tumorigenicity following differentiation, but also the aggressive
behavior of these ECCs following transplantation, and this effect
can be modulated in Pten mutants by actively forcing repression of
Nanog during differentiation in vitro.
The role of the PI3k pathway in regulating Nanog and Oct4
expression is well known [24,25,26]. In particular, culture of
murine ESCs for 8 days in the absence of LIF, and presence of
myristoylated-Akt (active form of Akt), results in the maintenance
of Oct4 and Nanog mRNA in the differentiating population and an
increase in the percentage of ESC-like colonies. However, the
proportion of undifferentiated colonies in the presence of active
Akt is lower when compared to culture in the presence of LIF
alone, suggesting that not every differentiated cell is capable of
retaining stem cell like characteristics when exposed to active Akt
in the absence of LIF [24]. Our data extend these findings to show
that under conditions of differentiation in the absence of LIF and
addition of RA, loss of Pten and increased phosphorylation of Akt
attenuate the repression of Nanog and Oct4 mRNA as previously
reported, but only in the emerging ECC population and not in the
general differentiated population. In a different study that
evaluated self-renewing ESCs in the presence of LIF, blocking
the PI3k pathway in murine ESCs caused repression of Nanog
mRNA and protein [25,26]. In agreement with this work but
under differentiating conditions in the presence of RA, we showed
that addition of Nanog siRNAs to Pten2/2 differentiating ESCs
significantly attenuated the emergence of ECCs from differenti-
ated cultures in vitro and the tumorigenicity of these cells in vivo,
therefore illustrating the importance of repressing Nanog down-
stream of the PI3k pathway to block ECC emergence during ESC
differentiation.
A novel aspect of our study was the finding that only a small
proportion of the Pten2/2 differentiating cells are sensitive to
retention of a stem cell-like state and retain elevated levels of
Nanog, while the majority of Pten2/2 cells initiate differentiation,
lose tumorigenicity and repress Nanog. One hypothesis for this
phenomenon is that the emerging ECCs identified in vitro are
transformed germ cells which also express SSEA1 and c-kit.
Support for this hypothesis is provided by the strong evidence that
spontaneous differentiation of ESCs in vitro consistently generates a
small population of germ cells within 3–5 days of culture
[27,28,29,30,31,32], together with the result that conditional loss
of Pten in fetal germ cells invariably causes teratomas from the
abnormal germ cells in vivo [33].
In the current study, microarray analysis of sorted SSEA1/c-kit
double positive population after differentiation revealed an
increase in pathways associated with glucose and cholesterol
metabolism. Furthermore, we show that Pten2/2 differentiated
cells have significantly higher levels of lactate than wild type. It is
known that activation of Akt increases intracellular ATP levels and
accelerates both glycolytic and oxidative metabolism (for review
see [20]). ESCs cultured under self- renewing conditions
proliferate quickly, yet appear to meet the majority of their
energy requirements by glycolysis similar to classic Warburg
cancer cells [22]. The increased intracellular lactate in differen-
tiated Pten2/2 cells relative to wild type suggests that these cells
have failed to effectively switch from glycolysis to oxidative
phosphorylation. The importance of transitioning from aerobic
glycolysis to oxidative phosphorylation during ESC differentiation
remains to be fully explored, and the role of Akt signaling in this
process warrants further investigation in light of its association
with increased tumorigenicity as described here.
A role for cholesterol in ESC self-renewal and differentiation is
now beginning to emerge. Previous studies have shown that
inhibiting cholesterol biogenesis with statins inhibits self-renewal of
Pten and Tumor Initiation after Differentiation
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16478
murine ESCs as well as genetically abnormal human ESCs, while
not affecting euploid hESC lines [34,35]. The importance of the
cholesterol pathway in mESC self-renewal has been associated
with the generation of intermediates required for post-translational
modification of RhoA and the Rock pathway [34]. This is a critical
link as Rock inhibitors have been shown to improve survival and
single cell cloning of hESCs under self renewing conditions
[36,37,38]. Together, this data suggests that cholesterol metabo-
lism and may also be critical for promoting increased survival and
growth of Pten2/2 ECCs under differentiating conditions, and
this warrants further investigation.
Our data further illuminate the hypothesis first suggested by
Harrison et. al. that ‘culture adaptation (and therefore neoplastic
progression) can occur through differing routes’ [11]. Together
this would suggest that multiple assays must be integrated in order
to predict neoplastic progression of PSC lines before a given line
can be used in regenerative medicine. In the current study we have
shown that deletion of a specific tumor suppressor, Pten resulted in
tumorigenicity specifically by promoting the emergence of a small
number of highly tumorigenic ECC cells in vitro, while the
remaining differentiated cells were non tumorigenic. Previously
reported pathways and mechanisms of neoplastic progression have
included failed senescence of differentiated transplanted cells [4],
increased survival of differentiated cells [8], increased numbers of
failed to differentiated cells [3], and aneuploidy [7]. The various
mechanisms behind each of these routes is equally critical to
understand in order to prevent PSCs that have undergone
neoplastic progression from being included in clinical use.
Taken together, the use of differentiation as the starting point to
measure neoplastic progression of PSC lines provides a novel
method for evaluating PSC tumorigenicity. In the current study
we discovered that a null mutation in a single gene, Pten, caused
teratomas from differentiated PSCs by promoting the survival of a
small population of highly tumorigenic ECC cells while the rest of
the population was non tumorigenic. The survival of these ECCs is
associated with failed repression of Nanog as well as a propensity for
increased glucose and cholesterol metabolism. In conclusion, the
identification of specific signaling pathways that contribute to
neoplastic progression of PSCs such as the one described here, are
vital as clinical applications for PSCs are currently at-hand.
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